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Rhabdomyosarcoma (RMS) and Ewing sarcoma (ES) are among the most common pedi-
atric sarcomas (Arndt et al., 2012). Despite sarcomas representing a highly heterogeneous
group of tumors, ES and alveolar RMS (ARMS) typically share one common genetic charac-
teristic, namely a speciﬁc chromosomal translocation (Helman and Meltzer, 2003; Lessnick
and Ladanyi, 2012).These translocations generate fusion proteins, which are composed of
two transcription factors (TF).Typically, oneTF is a developmentally regulated factor that is
essential for proper speciﬁcation of a given lineage and provides the DNA-binding domain,
while the partnerTF contributes a transactivation domain that drives aberrant expression
of target genes. Based on these common genetic characteristics, the ﬁrst ESF-EMBO
research conference entitled “Molecular Biology and InnovativeTherapies in Sarcomas of
Childhood and Adolescence” with special focus on RMS and ES was held at the Polo-
nia Castle in Pultusk, Poland.The conference gathered 70 participants from more than 15
countries and several continents representing most research groups that are active in this
ﬁeld.
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Alveolar RMS (ARMS) harbors reciprocal chromosomal translo-
cations between chromosome 2 (or chromosome 1) and chromo-
some 13, yielding t(2;13), or t(1;13). These translocations lead
to expression of characteristic fusion proteins that consist of the
DNA-binding domain of PAX3 or PAX7 and the transactivation
domain of the forkhead transcription factor FOXO1 on chromo-
some 13. Ewing sarcoma (ES) on the other hand is characterized
by a translocation involving the ubiquitously expressed, putative
RNA-binding EWSR1 gene and the friend leukemia integration 1
(FLI1) transcription factor,forming the EWS/FLI1 fusion protein
as the most common fusion event.
The genetic basis of these diseases is therefore thought to be
transcriptional deregulation of normal developmental processes.
Hence,improvingcurrenttreatmentapproacheswillrequirelikely
a more detailed understanding of the biology of these oncogenic
fusion proteins as well as of the underlying biology of the tumor
cells. Importantly, however, available mouse models for ARMS
using PAX3/FOXO1 as oncogenic driver as well as (so far unsuc-
cessful) attempts to generate a mouse model for ES based on
expression of EWS/FLI1 have unraveled the importance of largely
unknown secondary hits which are required for tumorigenesis.
Identiﬁcation of such secondary hits likely requires large-scale
next-generationsequencingof whichseveralprojectsarenowget-
ting under way. One critical challenge in this area, however, is the
availabilityof sufﬁcientandhigh-qualitytumorandnormaltissue
specimen.
Since transcription factors (TF) are thought to be undruggable
based on their overall structure and the complexity of eukary-
otic transcription, novel treatment approaches likely have to be
indirect. One such indirect possibility might lie in the epigenetic
control of gene expression which seems to play a major role also
in sarcomas, as discussed during the conference. Additional areas
that are beginning to emerge are the detailed characterization of
the role played by embryonal signaling pathways such as Wnt,
Notch,and Hedgehog (Hh) in tumorigenesis of sarcomas.
TUMOR BIOLOGY OF SARCOMA
Different levels of gene regulation by EWS/FLI1 were discussed
by H. Kovar (Vienna, Austria) who also investigated the role of
the Notch pathway in ES. O. Delattre (Paris, France) described
their attempts to generate a mouse model for ES and also
described identiﬁcation of an additional novel translocation,
BCOR-CCNB3. The next two talks under this topic looked at spe-
ciﬁc aspects in rhabdomyosarcoma (RMS), namely the biological
role of CB1, a well-known downstream target gene. Interest-
ingly, inhibition of CB1 was found to abrogate lung metastasis
in a xenograft mouse model (G. Grosveld, Memphis, TN, USA).
Finally, S. Hettmer (Boston, MA, USA) reported on a promis-
ing in vitro system that allows transformation of primary satellite
cells by speciﬁc oncogenes such as RAS together with deletion
of CDKN2A, thereby creating a deﬁned RMS tumorigenicity
model.
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TRANSCRIPTIONAL CONTROL AND EPIGENETICS
S. Lessnik (Salt Lake City, UT, USA) discussed a novel target gene
repressed by EWS/FLI1, namely lysyl oxidase (LOX) that inhibits
the transformed phenotype of ES cells. For transcriptional repres-
sion, association of EWS/FLI1 with histone deacetylases and the
NuRD complex were identiﬁed as necessary elements. As a com-
ponent of the Wnt signaling pathway, DKK2 was reported by G.
Richter (Munich, Germany) to be highly overexpressed in ES and
critical for malignant cell outgrowth in vitro and in vivo.
Apart from histone acetylation, also histone methylation is an
important epigenetic mechanism contributing to genetic hetero-
geneity. E. Lawlor (MI, USA) described studies investigating the
role of the polycomb repressor complex in response to EWS/FLI1
expression. Finally, activity of the fusion TF might also be reg-
ulated by protein–protein interactions. One interesting co-factor
to follow up in the future might be E2F (R. Schwentner, Vienna,
Austria).
IDENTIFICATION OF NOVEL CRITICAL PATHWAYS IN
SARCOMA BIOLOGY
T. Triche (Los Angeles, CA, USA) discussed the prognostic signif-
icance of non-coding RNA identiﬁed by a human exon array. In
ES,ErbB4 might play a role in metastasis (P. Sorensen,Vancouver,
BC,Canada),whilecul4,anE3-ubiquitinligase,mighthaveagen-
eral role in ES (C. Mackintosh, Salamanca, Spain). In RMS, novel
pathways that were subject of discussion included the role of pro-
proteinconvertaseswhichareinvolvedinprocessingof important
therapeutictargetssuchasIGF1R(M.Bernasconi,Zurich,Switzer-
land). Several novel target genes of PAX3/FOXO1 were character-
izedbydifferentgroupssuchascarnitinepalmitoyltransferaseand
pleiotrophin (T. Chen, Memphis, TN, USA), JARID2 (J. Shipley,
Sutton, UK), and p-cadherin (C. Gauthier-Rouviere, Montpellier,
France). Genome-wide ChIP-seq experiments could also help to
identify novel critical pathways. Such experiments were presented
by L. Cao (Washington, DC, USA) for PAX3/FOXO1. Among
the important receptor targets that he identiﬁed as direct targets
of the fusion protein were FGFR4, c-MET, IGFR1R, and TRAIL
receptor 2. Interestingly,about 25% of the identiﬁed binding sites
seem to lie in the ﬁrst intron and some even further downstream
within genes. Another important new ﬁeld for sarcoma biology
is the role of miRNAs in the tumorigenic process. Some miRNA
termed the myomiRs are important for myogenic differentiation
and hence RMS biology. These include miR206 and miR1 which
were discussed by S. Subramanian (Minneapolis, MN, USA) and
C. Ponzetto (Torino, Italy).
RESISTANCE MECHANISMS AND CANCER STEM CELLS
Despite its relevance for tumor biology, characterization of can-
cer stem cells in sarcoma is still in its infancy. Attempts to
deﬁne a subpopulation of ES cells by side-population analysis
were discussed by M. Hotﬁlder (Muenster, Germany). Evasion of
apoptosis, one of the hallmarks of human cancers, can also be
the cause of treatment resistance. Indeed, sensitivity of sarcoma
cells to treatment with TRAIL was reported by two researchers
(S. Fulda, Frankfurt, Germany and F. Redini, Nantes, France).
Along similar lines, blockade of survivin might enhance sensitiv-
ity to therapeutic T cells (K. Simon-Keller,Mannheim,Germany).
P. Zammit (London, UK) described an in vitro culture system
of isolated single muscle ﬁbers that contained satellite cells in
their natural niche. Ectopic expression of PAX3/FOXO1 was able
to induce expression of myogenin but not myoD. However, it
remained unclear whether the satellite cells become fully trans-
formed. D. Loeb (Baltimore, MD, USA) then looked at another
interestinggeneinthecontextof ES,namelyWT1.Thistranscrip-
tion factor might play an important role for angiogenesis in this
tumor.
ANIMAL MODELS OF RMS
An important tool not only to advance our understanding of
tumorbiologybutalsotoprioritizedrugsforpre-clinicaldevelop-
ment is the availability of genetically engineered animal models.
While no mouse model is available up to now for ES that is dri-
ven by the EWS/FLI1 oncogene, C. Keller (Portland, OR, USA)
described mice expressing PAX3/FOXO1 that will form ARMS in
collaboration with p53 deletion. Interestingly, he used different
driver genes along the myogenic lineage to initiate expression of
the fusion protein and found the most penetrating model to be
with myf6. From this data he concluded that the cell of origin
for ARMS is a fetal myoblast. In contrast to ARMS,several mouse
models are available that give rise to ERMS, the RMS subtype
without expression of the fusion protein. H. Hahn (Goettingen,
Germany) reported on recent ﬁndings in the Ptch heterozygous
mouse model that leads to activation of the Hh pathway and
ERMS. An interesting zebraﬁsh model utilizing activated K-RAS
was discussed by D. Langenau (Boston, MA, USA). This model
allowsinvivoimagingofdevelopingtumors.Whilenotallcellsina
tumor might have tumor-propagating potential,these cells clearly
can enter the vasculature and play a critical role in metastasis, at
least in zebraﬁsh.
FUSION PROTEINS AS THERAPEUTIC TARGETS
J. Toretsky (Washington, DC, USA) discussed interaction of
EWS/FLI1 with RNA helicase A which could be utilized as thera-
peutic target and the improvements that were made in develop-
ing a speciﬁc small therapeutic molecule. Another approach was
described by B. Schäfer (Zurich, Switzerland) who investigated
post-translational modiﬁcations of PAX3/FOXO1. Several phos-
phorylation sites were identiﬁed and a candidate upstream kinase
(PLK1) was identiﬁed that might regulate PAX3/FOXO1 activity.
The same phosphorylation sites were also investigated biochem-
ically in much more detail by A. Hollenbach (New Orleans, LA,
USA). Finally, the role of gene ampliﬁcation in the pathogenesis
of RMS was addressed by F. Barr (Bethesda, MD, USA).
TARGETING SIGNAL TRANSDUCTION
Several important signaling pathways were highlighted in this ses-
sion. These included a CRKL/Yes axis (L. Helman, Bethesda, MD,
USA),targeting of c-Met by a small-molecule inhibitor (S.J. Ding,
NE, USA) and the inﬂuence of the Notch pathway on invasion
of RMS cells (J. Roma, Barcelona, Spain). The possibility of tar-
geting both tumor and stromal cells by inhibiting the PDGFR
pathway was brought up by M. Ehman (Stockholm, Sweden).
A new and exciting area of research is represented by the newly
discovered ALK mutations that occur in RMS and which can
Frontiers in Oncology | Pediatric Oncology June 2013 | Volume 3 | Article 142 | 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schäfer et al. Meeting report
be targeted by small-molecule inhibitors (Y. Versleijen-Jonkers,
Nijmegen, Netherlands).
NEW DRUGS – PRE-CLINICAL AND CLINICAL EVALUATION
The last two sessions of the conference closed the circle to dis-
cuss potentially novel treatment options. The ﬁrst talk in this
session was given by P. Houghton (Columbus, OH, USA) who
summarized the efforts made by the Pediatric Pre-clinical Testing
Program (PPTP) to identify important novel drugs for sarcoma
treatment. Interestingly, response rates for known drugs in the
xenograftmodelsarearound30%,whileitwasonly9%forexperi-
mentaldrugs.Forsarcomas,oneimportantclassofdrugsmightbe
topoisomerase I inhibitors. Furthermore,inhibition of the IGF1R
resulted in suppression of sarcoma growth. Since the PPTP pro-
gramworkswithanimalmodels,itwillbecrucialtodevelopstrate-
giesforclinicaltranslation.J.Chisholm(Sutton,UK)describedthe
structure used in Europe to achieve this goal, and which is called
ITCC (innovative treatments for children with cancer). Several
trials are now implemented under this umbrella. One of the tar-
gets that are currently being developed at the Royal Marsden was
discussed in the ﬁnal talk by S. Gatz (Sutton, UK), namely FGFR,
which was found mutated in some ARMS and overexpressed in
most of them.
CLINICAL RESEARCH
Moving further to the clinics, U. Dirksen (Muenster, Germany)
summarized the current state of the art on diagnosis, treatment
and prognostic factors for ES in Europe. E. Koscielniak (Stuttgart,
Germany) gave an overview on the role of molecular signatures in
soft tissue sarcoma and their impact on therapy stratiﬁcation of
RMS. S. Stegmaier (Stuttgart, Germany) discussed the prognostic
relevanceoffusiontranscriptmarkersinsofttissuesarcoma.Some
discrepancy in the ﬁeld concerns the clinical outcome of different
PAX/FOXO1 fusions,as different outcomes depending on distinct
PAX/FOXO1 fusion products have been found in the US, but not
in the European CWS trials. Finally, a novel fusion transcription
factor, EWSR1/NFAT2c was described in ES (K. Szuhai, Leiden,
Netherlands).
CONCLUSION
This conference was the ﬁrst specialized international meeting
that brought together leading biologists and clinicians involved
in early clinical trials to discuss recent advances in translational
cancer research on two groups of sarcomas, namely RMS and
ES, in the pediatric and young adult population. Since fusion
TF are often the only genetic abnormality present at high fre-
quency in these tumors, they are hypothesized to be one of the
tumor-initiating events and might represent important therapeu-
tic targets. Therefore,a large effort is still directed at identiﬁcation
ofspeciﬁc,eitheractivatedorrepressedtargetgenes.Severalspeak-
ersdiscussednoveltechniquessuchasnext-generationsequencing
and whole genome ChIP-seq to identify such target genes includ-
ing mechanisms of transcriptional regulation. Several new targets
genes that have now been individually characterized were high-
lighted as novel therapeutic targets at the conference. Another
important area in this ﬁeld is the development of genetic animal
modelstofurtheradvanceourunderstandingof thebiologyof the
diseases and to pre-clinically evaluate novel targeted compounds.
A speciﬁc session addressed the progress in this ﬁeld spanning
from mouse to zebraﬁsh models. Especially for ES, the lack of an
appropriate mouse model still represents a major bottleneck.
In two forward-looking sessions, future research directions
were discussed. Among them were methods to unravel the still
unknowncellof originforthesesarcomas.Novelinsightsintothis
aspect might be provided by future collaborations with develop-
mental biologists. Additional identiﬁed areas included the search
for novel genetic alterations, the role of the micro- and macroen-
vironment, the signiﬁcance of tumor heterogeneity and pharma-
cogenomics. Regarding novel therapeutic targets, more emphasis
might be put on understanding the biology of the prevalent
genetic aberrations found in these tumors, namely the fusion TF
themselves. However,important downstream target genes include
some well-known oncogenes against which direct inhibitors are
available and therefore development of therapies using these tar-
gets might be more straightforward. Hopefully, a next confer-
ence planned 2years from now will further prioritize the most
promising therapeutic avenues.
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